Literature DB >> 8006042

Post-translational requirements for functional factor V and factor VIII secretion in mammalian cells.

D D Pittman1, K N Tomkinson, R J Kaufman.   

Abstract

Coagulation factors V and VIII are homologous glycosylated plasma proteins that provide essential functions for hemostasis. Factor V is secreted as a single chain polypeptide, whereas factor VIII is processed intracellularly to yield a metal-ion-associated heterodimer that is stabilized through interaction with von Willebrand factor. In transfected mammalian cells, factor V is more efficiently secreted than factor VIII. To provide insight into the different secretion efficiencies, we compared the post-translational processing requirements for factor V and factor VIII expressed in mammalian cells. In contrast to factor VIII, factor V was not detected in association with the immunoglobulin-binding protein (BiP), a chaperonin protein of the endoplasmic reticulum (ER). Depletion of intracellular ATP levels by treatment of cells with low concentrations of carbonyl cyanide 3-chlorophenylhydrazone (CCCP), protonophore that uncouples oxidative phosphorylation, inhibited secretion of factor VIII but had no effect on the secretion of factor V. Inhibition of N-linked oligosaccharide addition by treatment with tunicamycin prevented secretion of both factor V and factor VIII, whereas treatment with an inhibitor of complex oligosaccharide addition, deoxymannojirimycin, did not affect secretion, although the specific activities of both factor V and factor VIII were slightly increased. Thus, complex oligosaccharide addition was not required for secretion or functional activity of either factor V or factor VIII. Depletion of intralumenal calcium with the ionophore A23187 did not affect secretion of either factor V or factor VIII. In the presence of A23187, the secreted factor V was fully functional, whereas the factor VIII heavy and light chains were not associated and the secreted molecule was inactive. In addition, A23187 treatment inhibited addition of serine/threonine (O)-linked oligosaccharides to factor V and factor VIII. The differences between factor V and factor VIII were further evaluated by characterization of a single chain mutant factor VIII. The single chain factor VIII was secreted with an efficiency similar to wild-type factor VIII and also required von Willebrand factor for stabilization. In addition, the activity of single chain factor VIII was also inhibited by A23187 treatment, suggesting a unique metal-ion requirement within the secretory pathway for functional factor VIII folding. The differences identified in BiP association, ATP requirements, and metal-ion dependence for effective functional secretion of these two molecules may underlie mechanisms accounting for their different secretion efficiencies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8006042

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels.

Authors:  Kevin R Viel; Deepa K Machiah; Diane M Warren; Manana Khachidze; Alfonso Buil; Karl Fernstrom; Juan C Souto; Juan M Peralta; Todd Smith; John Blangero; Sandra Porter; Stephen T Warren; Jordi Fontcuberta; Jose M Soria; W Dana Flanders; Laura Almasy; Tom E Howard
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

Review 2.  A review of the mammalian unfolded protein response.

Authors:  Anirikh Chakrabarti; Aaron W Chen; Jeffrey D Varner
Journal:  Biotechnol Bioeng       Date:  2011-08-09       Impact factor: 4.530

3.  Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.

Authors:  Joshua I Siner; Benjamin J Samelson-Jones; Julie M Crudele; Robert A French; Benjamin J Lee; Shanzhen Zhou; Elizabeth Merricks; Robin Raymer; Timothy C Nichols; Rodney M Camire; Valder R Arruda
Journal:  JCI Insight       Date:  2016-10-06

4.  The effect of Arg306-->Ala and Arg506-->Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S.

Authors:  J O Egan; M Kalafatis; K G Mann
Journal:  Protein Sci       Date:  1997-09       Impact factor: 6.725

5.  Bioengineering of coagulation factor VIII for efficient expression through elimination of a dispensable disulfide loop.

Authors:  S R Selvaraj; A N Scheller; H Z Miao; R J Kaufman; Steven W Pipe
Journal:  J Thromb Haemost       Date:  2012-01       Impact factor: 5.824

6.  Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein.

Authors:  Ryan J Summers; Shannon L Meeks; John F Healey; Harrison C Brown; Ernest T Parker; Christine L Kempton; Christopher B Doering; Pete Lollar
Journal:  Blood       Date:  2011-01-07       Impact factor: 22.113

7.  Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII.

Authors:  Matthew P Kosloski; Razvan D Miclea; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2009-06-05       Impact factor: 4.009

8.  Enhanced Proteolytic Processing of Recombinant Human Coagulation Factor VIII B-Domain Variants by Recombinant Furins.

Authors:  Marcos A Demasi; Erika de S Molina; Christian Bowman-Colin; Fernando H Lojudice; Angelita Muras; Mari C Sogayar
Journal:  Mol Biotechnol       Date:  2016-06       Impact factor: 2.695

9.  The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene.

Authors:  Lingxia Chen; Fuxiang Zhu; Juan Li; Hui Lu; Haiyan Jiang; Rita Sarkar; Valder R Arruda; Jinhui Wang; Jennifer Zhao; Glenn F Pierce; Qiulan Ding; Xuefeng Wang; Hongli Wang; Steven W Pipe; Xiang-Qin Liu; Xiao Xiao; Rodney M Camire; Weidong Xiao
Journal:  Mol Ther       Date:  2007-07-24       Impact factor: 11.454

10.  Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα.

Authors:  Lisa M Vincent; Sinh Tran; Ruzica Livaja; Tracy A Bensend; Dianna M Milewicz; Björn Dahlbäck
Journal:  J Clin Invest       Date:  2013-08-27       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.